ARM Innovation Hub
Advertisement: RSM
Advertisement: Mogrify mid banner
Advertisement: Simpsons Creative
RealVNC mid banner careers
Advertisement: EY Mid banner
Advertisement: Kao Data Centre mid banner
Advertisement: TTP
Advertisement: Cambridge Network
Mid banner advertisement: BDO
Advertisement: Wild Knight Vodka
RealVNC mid-banner general
Barr Ellison Solicitors – commercial property
Advertisement: EBCam mid banner
23 July, 2020 - 10:22 By Tony Quested

Talented twosome promoted by Amadeus Capital Partners

Amadeus Capital Partners Amelia Armour and Pierre Socha

Global technology investor Amadeus Capital Partners – which has major operations in Cambridge – has promoted Amelia Armour and Pierre Socha to partner status in its Early Stage Fund team.

Since 1997, the firm has raised over $1 billion for investment and used it to back 145 companies.

Pioneering businesses it has backed include cyber security vendor ForeScout (NASDAQ:FSCT); Graphcore, innovators in intelligent microprocessors; IVF genetic testing company, Igenomix, IndiaMART, the B2B online marketplace (NSE: INDIAMART) and speech recognition company VocalIQ (acquired by Apple).

Armour joined Amadeus in 2009. Her investment focus is on autonomous systems, AI and machine learning, cloud computing, digital health and medical technology. 

She is a director on the boards of Sprout.ai, Xampla, Cambridge Touch Technologies, Paragraf, Immense Simulations, Baby2body, Riverlane and SLAMcore. She is also a board observer at PROWLER.io and Graphcore.

She said: “I’m delighted to be recognised, having been supported by the great team at Amadeus over the past 10 years. The most fulfilling part of the role is working with our portfolio companies to build global enterprises. I’m looking forward to working with many more ground-breaking startups across the UK.”

Socha joined Amadeus in 2012 and manages early stage health and biotech investments for Amadeus. He is on the boards of Quibim, Inotec, Ori Biotech, Doctify, Congenica, PhoreMost and oversees its investments in Lumeon and Organox.

He said: “Amadeus has been front and centre of deep technology investment for decades. I’m grateful to be given the opportunity to lead our early stage activities in biotech, medtech and digital health. 
“We’re planning to grow our team and will keep pushing the boundaries in emerging tech investing.”

Newsletter Subscription

Stay informed of the latest news and features